HCWB
HCW Biologics Inc. NASDAQ Listed Jul 20, 2021$1.09
After hrs
$1.10
+0.74%
Mkt Cap $2.3M
52w Low $0.27
14.3% of range
52w High $6.02
50d MA $1.00
200d MA $1.84
P/E (TTM)
-0.1x
EV/EBITDA
—
P/B
0.8x
Debt/Equity
2.5x
ROE
-287.9%
P/FCF
-0.2x
RSI (14)
17.00
ATR (14)
$0.19
Beta
0.91
50d MA
$1.00
200d MA
$1.84
Avg Volume
24.9M
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
2929 North Commerce Parkway · Miramar, FL 33025 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -0.84 | -2.63 | -213.1% | 0.36 | -8.3% | -16.7% | -10.7% | +7.3% | -5.0% | +20.2% | — |
| Nov 14, 2025 | AMC | 1.58 | -2.02 | -227.8% | 3.00 | +0.7% | +2.0% | -21.2% | -17.0% | -4.0% | +13.0% | — |
| Aug 18, 2025 | AMC | 1.80 | -6.79 | -477.2% | 4.02 | -10.0% | -11.4% | -4.5% | -2.6% | +4.2% | +60.9% | — |
| May 15, 2025 | AMC | — | -0.05 | — | 8.20 | +0.0% | +9.1% | -4.2% | +7.1% | -5.2% | -4.5% | — |
| Mar 28, 2025 | AMC | 3.60 | -3.20 | -188.9% | 12.00 | -5.7% | -6.0% | -0.4% | +0.3% | -15.3% | -4.8% | — |
| Nov 14, 2024 | AMC | -5.20 | -4.00 | +23.1% | 12.36 | -8.4% | -4.7% | +321.1% | -11.3% | -13.9% | -25.1% | — |
| Aug 14, 2024 | AMC | -7.20 | -16.00 | -122.2% | 23.20 | -13.8% | -13.6% | -0.2% | +0.0% | -11.0% | -3.6% | — |
| May 15, 2024 | AMC | — | -8.00 | — | 46.40 | -4.3% | -5.2% | +0.0% | +0.9% | +0.0% | +0.0% | — |
| Mar 26, 2024 | AMC | — | -0.15 | — | 68.00 | -4.1% | +3.5% | -0.6% | -5.7% | +0.6% | +0.0% | — |
| Nov 14, 2023 | AMC | -0.13 | -5.60 | -4207.7% | 46.40 | +0.0% | -20.7% | +15.2% | +3.3% | -1.4% | +0.9% | — |
| Aug 11, 2023 | AMC | -0.15 | -4.80 | -3100.0% | 84.80 | -1.7% | +0.5% | -2.2% | +0.8% | -3.8% | -0.0% | — |
| May 9, 2023 | AMC | -0.14 | -5.60 | -3900.0% | 59.60 | -4.3% | +3.4% | -2.6% | +1.3% | -3.3% | +1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 29 | Maxim Group | Maintains | Buy → Buy | — | $8.00 | $8.00 | +0.0% | +0.2% | -3.6% | -6.7% | -7.1% | -8.4% |
| Apr 19 | EF Hutton | Maintains | Buy → Buy | — | $59.60 | $58.40 | -2.0% | -2.0% | -6.2% | +1.1% | +2.2% | -1.4% |
| Mar 30 | EF Hutton | Maintains | Buy → Buy | — | $58.40 | $62.40 | +6.8% | -8.9% | +5.3% | -2.9% | +3.7% | +2.8% |
| Mar 23 | EF Hutton | Maintains | Buy → Buy | — | $54.00 | $60.80 | +12.6% | +7.4% | -4.1% | -1.8% | -2.6% | +9.8% |
| Nov 8 | JonesTrading | Maintains | Buy → Buy | — | $91.20 | $89.60 | -1.8% | -2.3% | +4.1% | -3.0% | -3.1% | -1.1% |
| Mar 24 | Maxim Group | Maintains | Buy → Buy | — | $91.20 | $96.40 | +5.7% | +3.9% | +8.9% | -6.6% | +2.1% | +2.4% |
| Nov 19 | EF Hutton | Maintains | Buy → Buy | — | $114.40 | $119.20 | +4.2% | +2.8% | -8.8% | -2.6% | +8.0% | -3.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 22, 2026 | Wong Hing CDir/Off | Chief Executive Officer | Buy | 113,879 | $1.41 | $160K | 615,790 | +7.73% | -6.15% |
| May 22, 2026 | GARRETT SCOTT TDir | — | Buy | 177,936 | $1.41 | $250K | 203,441 | +7.73% | -6.15% |
| May 22, 2026 | Byam RebeccaOff | Chief Financial Officer | Buy | 14,235 | $1.41 | $20K | 57,245 | +7.73% | -6.15% |
8-K · 7.01
! Medium
HCW Biologics Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 16
8-K
HCW Biologics Inc. -- 8-K Filing
Jun 15
8-K
HCW Biologics Inc. -- 8-K Filing
HCW Biologics has until September 22, 2026, to regain Nasdaq compliance on the Bid Price Rule or face immediate delisting, with potential extensions available for other listing violations.
Jun 1
8-K · 1.02
!! High
HCW Biologics Inc. -- 8-K 1.02: Material Agreement Terminated
May 27
8-K · 1.01
!! High
HCW Biologics Inc. -- 8-K 1.01: Material Agreement
May 21
8-K · 8.01
!! High
HCW Biologics Inc. -- 8-K 8.01: Material Event / Announcement
HCW Biologics failed to achieve quorum at its special stockholder meeting, preventing any votes on proposed matters and potentially delaying critical corporate actions.
Apr 30
8-K · 5.03
! Medium
Unknown — 8-K 5.03: Amendment to Articles / Bylaws
HCWB amended its bylaws, likely reflecting internal governance changes that could affect shareholder rights, board procedures, or management structure—investors should review specific amendments for potential impacts on voting power or operational control.
Apr 16
8-K
Unknown — 8-K Filing
HCW Biologics reported Q4 2025 results as a clinical-stage biotech, meaning investors are betting on future drug approvals rather than current revenue, carrying significant execution and regulatory risk.
Mar 31
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
HCWB secured two exclusive licensing agreements worth $7.0 million, providing new revenue streams and potentially expanding its product portfolio, which could drive near-term growth and improve profitability margins.
Mar 17
8-K
HCW Biologics Inc. -- 8-K Filing
HCW Biologics faces imminent delisting from Nasdaq due to noncompliance with listing standards, with the exchange staff set to issue a Delist Determination Letter and the company unable to cure the deficiency.
Mar 2
8-K · 8.01
!! High
HCW Biologics Inc. -- 8-K 8.01: Material Event / Announcement
This 8-K filing by HCW Biologics (HCWB) contains only standard legal disclaimers about securities offerings, providing no material information about company events or business developments affecting investors.
Feb 19
8-K · 1.01
!! High
HCW Biologics Inc. -- 8-K 1.01: Material Agreement
HCW Biologics secured an exclusive worldwide license agreement with WY Biotech for HCW11-006's in vivo applications, generating upfront revenue and potential milestone payments plus a Greater China option.
Feb 13
Institutional (13F) — Top 7
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Hrt Financial Lp | 266,393 | $95K | New | Mar 2026 |
| 2 | Citadel Advisors Llc | 26,083 | $9K | Added | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 12,023 | $4K | New | Mar 2026 |
| 4 | Ubs Group Ag | 9,221 | $3K | Added | Mar 2026 |
| 5 | Wells Fargo & Company/mn | 1,000 | $360 | New | Mar 2026 |
| 6 | Virtu Financial Llc | 47,809 | $17 | New | Mar 2026 |
| 7 | Citigroup Inc | 1 | $1 | Reduced | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 4
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 10,180 | $6K | Feb 2026 |
| 2 | Fidelity Series Total Market Index Fund | 1,488 | $804 | Feb 2026 |
| 3 | Fidelity Total Market Index Fund | 726 | $392 | Feb 2026 |
| 4 | Fidelity Nasdaq Composite Index Fund | 412 | $223 | Feb 2026 |
Valuation
Market Cap
$2.3M
Enterprise Value
$334K
P/E (TTM)
-0.10x
Forward P/E
—
PEG Ratio
-0.00x
P/B
0.83x
P/S
42.16x
P/FCF
-0.17x
EV/EBITDA
—
Shares Out
2.1M
Financials (TTM)
Revenue
$54K
Net Income
-$8.0M
EBITDA
-$5.7M
Free Cash Flow
-$13.4M
Op Cash Flow
-$13.4M
EPS Basic
$-10.63
EPS Diluted
$-10.63
EPS Forward
$-0.96
Gross Margin
20.0%
Op Margin
-20757.7%
Net Margin
-14677.1%
Balance Sheet
Total Assets
$24.5M
Total Liab.
$21.8M
Total Equity
$2.8M
Cash
$2.0M
LT Debt
$0
Book Value/Sh
$1.32
Debt/Equity
2.46x
Current Ratio
0.11
Quick Ratio
0.11
Returns & Growth
ROE
-287.9%
ROA
-32.5%
ROIC
-109.7%
Rev Growth YoY
-97.9%
EPS Growth YoY
-1280.5%
Price Returns
2W
+487.5%
1M
+320.2%
3M
+266.3%
6M
-6.6%
12M
-74.4%
Technicals
52W High
$6.02
52W Low
$0.27
50d MA
$1.00
200d MA
$1.84
RSI (14)
17.00
ATR (14)
$0.19
Beta
0.91
Avg Volume
24.9M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 1:14pm
· Source: financialmodelingprep.com